He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences (GILD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after market close. Leerink ...

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...